PMID- 7909941
OWN - NLM
STAT- MEDLINE
DCOM- 19940609
LR  - 20181130
VI  - 36 Suppl 1
DP  - 1994
TI  - Taxoids: a new class of cytotoxic agents.
PG  - S25-8
AB  - Taxoids (paclitaxel and docetaxel) are a new class of cytotoxic agents. Their 
      mechanism of action (enhanced polymerization of tubulin and inhibition of its 
      depolymerization) acts thereby as mitotic spindle inhibitors. Significant 
      experimental antitumor activity, although more marked with docetaxel, has been 
      observed with both agents. Their main side-effects are reversible non cumulative 
      neutropenia and alopecia; significant hypersensitivity reactions using 
      cortico-steroids antiHT1/2 premedication are seen in < 5% of patients receiving 
      paclitaxel as a pulsed (3 h) infusion; neurotoxicity appears dose-related; 
      docetaxel can induce a peculiar skin toxicity often associated with edema. 
      Paclitaxel at the recommended dose of 175 mg/m2 achieves responses in 20-30% of 
      patients with relapsed ovarian carcinoma; its activity in advanced breast cancer 
      although significant is clearly dose-related with an optimal dose still 
      debatable; responses are observed in approximately 30% of patients with non small 
      cell lung cancer (NSCLC). Docetaxel (100 mg/2) is active in first line treatment 
      of advanced breast cancer (50-72% RR) as well as 2nd line treatment (> 40% RR); 
      an activity in the range of that observed with paclitaxel is reported in NSCLC.
FAU - Marty, M
AU  - Marty M
AD  - Service d'Oncologie Medicale, Hopital Saint Louis, Paris, France.
FAU - Extra, J M
AU  - Extra JM
FAU - Giacchetti, S
AU  - Giacchetti S
FAU - Cuvier, C
AU  - Cuvier C
FAU - Espie, M
AU  - Espie M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Nouv Rev Fr Hematol (1978)
JT  - Nouvelle revue francaise d'hematologie
JID - 7909092
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Phytogenic/classification/*therapeutic use/toxicity
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Docetaxel
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Humans
MH  - Neoplasms/drug therapy
MH  - Paclitaxel/*analogs & derivatives/*therapeutic use/toxicity
MH  - *Taxoids
RF  - 17
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Nouv Rev Fr Hematol (1978). 1994;36 Suppl 1:S25-8.